This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Androgen receptor signalling inhibitors in prostate cancer and cardiovascular risk

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Androgen receptor signalling inhibitors receptors in prostate cancer and cardiovascular risk:

  • a systematic review and meta-analysis of 24 randomized clinical trials involving 22 166 patients found that the addition of androgen receptor signalling inhibitors alongside standard androgen deprivation therapy was associated with significantly increased risk of men experiencing cardiovascular events (1)
    • study selection included randomized clinical trials of ARSI agents (abiraterone, apalutamide, darolutamide, enzalutamide) that reported CV events among individuals with M0 and M1, hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer (CRPC)
    • it was found that addition of androgen receptor signalling inhibitors to traditional androgen deprivation therapy was associated with an increased risk of all-grade (RR 1.75; 95% CI 1.50-2.04; P < 0.001) and grade ≥3 (2.10; 1.72-2.55; P <0.001) CV events

Reference:

  1. El-Taji O, Taktak S, Jones C, Brown M, Clarke N, Sachdeva A. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. JAMA Oncol. Published online June 06, 2024. doi:10.1001/jamaoncol.2024.1549

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page